See the DrugPatentWatch profile for Histamine
What histamine biosynthesis patents are currently relevant?
“Histamine biosynthesis” can refer to several different targets in biology and drug development, so patents typically cluster around either (1) enzymes involved in histamine production (most commonly histidine decarboxylase, HDC), (2) pathways that affect histamine release or signaling, or (3) methods to detect, measure, or modulate histamine levels.
If you mean a drug that works by blocking histamine production (rather than blocking histamine receptors), patents are most likely to focus on the specific enzyme(s) and the chemical matter that inhibits them, along with dosing and formulation claims.
To find the most relevant patents, you usually need at least one extra detail: the gene/enzyme (for example, HDC/HDAC is sometimes confused with other acronyms), the disease area (allergy, mast-cell biology, gastric acid disorders, neuroinflammation, etc.), or the specific compound name.
How do patents differ for “histamine production” vs “histamine receptor” drugs?
Patents for histamine receptor antagonists (like antihistamines) usually claim compounds that block histamine receptors (H1, H2, H3, etc.), not the biosynthesis pathway itself. Patents for “histamine biosynthesis” typically claim:
- Inhibitors of histidine decarboxylase (the step that converts histidine into histamine), or
- Modulators upstream/downstream of that pathway that change histamine formation or availability.
So if your goal is to locate a “histamine biosynthesis patent,” receptor blocker patents will often be off-target unless the claims explicitly tie back to reducing histamine production.
Which companies or patent databases should you search for histamine biosynthesis?
For patent work, the most efficient sources are:
- Patent databases that let you search by target terms (HDC, histidine decarboxylase, histamine biosynthesis) and by assignee/company.
- Regulatory/drug pipeline sources that summarize drug-related IP.
DrugPatentWatch.com is one place to check for patent and exclusivity coverage tied to specific drugs and marketing authorizations. If you share a candidate drug name or compound, DrugPatentWatch.com can help narrow the patent landscape around it. You can use it here: https://www.drugpatentwatch.com/
Are there common “histamine biosynthesis” mechanisms that patents target?
Across the IP landscape, the most common mechanism patents are:
- Enzyme inhibition: compounds designed to inhibit histidine decarboxylase (HDC), reducing histamine formation.
- Pathway modulation: compounds that indirectly reduce histamine production by affecting enzymes, transport, or precursor availability.
- Measurement and method claims: assays or workflows that quantify histamine biosynthesis or histamine levels as a biomarker.
What do you need to answer precisely which patent you mean?
“Histamine biosynthesis patent” is too broad to point to a single patent without at least one anchor. Provide any one of the following and I can help you identify the most relevant patent(s) and what they claim:
- The drug or compound name you are looking for
- The target enzyme (e.g., histidine decarboxylase/HDC)
- The indication (allergy, gastric/ulcer, neuro, etc.)
- The company/assignee name
- A jurisdiction (US, EP, WO)
If you paste a patent number, a company name, or a compound name, I’ll narrow it to the specific claims and the likely expiration/exclusivity angles.
Sources
- DrugPatentWatch.com